Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Long-Term Deferred Tax (2021 - 2022)

Pasithea Therapeutics (KTTA) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $4.2 million as the latest value for Q4 2022.

  • Quarterly Long-Term Deferred Tax rose 346.29% to $4.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2022, up 346.29% year-over-year, with the annual reading at $4.2 million for FY2022, 346.29% up from the prior year.
  • Long-Term Deferred Tax hit $4.2 million in Q4 2022 for Pasithea Therapeutics, up from $931000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $4.2 million in Q4 2022 to a low of $931000.0 in Q4 2021.